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Abstract
The heart is the first organ to develop in the embryo, and its formation is an
exquisitely regulated process. Inherited mutations in genes required for cardiac
development may cause congenital heart disease (CHD), manifested in the
newborn or in the adult. Notch is an ancient, highly conserved signaling pathway
that communicates adjacent cells to regulate cell fate specification, differentia-
tion, and tissue patterning. Mutations in Notch signaling elements result in
cardiac abnormalities in mice and humans, demonstrating an essential role for
Notch in heart development. Recent work has shown that endocardial Notch
activity orchestrates the early events as well as the patterning and morphogenesis
of the ventricular chambers in the mouse and that inactivating mutations in the
NOTCH pathway regulator MIND BOMB-1 (MIB1) cause left ventricular
non-compaction (LVNC), a cardiomyopathy of poorly understood etiology.
Here, we review these data that shed some light on the etiology of LVNC that
at least in the case of that caused byMIB1 mutations has a developmental basis.
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Heart development begins in the mouse at embryonic day 7 (E7) when pre-cardiac
precursor cells move forward bilaterally into the lateral plate mesoderm to form the
cardiac crescent [14]. By E8, a linear heart tube is formed after folding of the
mesodermal layers from both sides of the embryo, and the two main tissues of the
heart are present, the endocardium inside and the outer myocardium. At E9.0, the
heart loops and grows by addition of cells from both cardiac poles [20]. At E9.5, the
heart divides afterward into developmental domains that would allow the formation
of two regions, the valve and the chamber regions [24] (Fig. 12.1a).
We will describe in some detail the process of ventricular chamber development
because it is the focus of this review. At E9.5, the process of trabeculation begins in
the primitive ventricles. Trabeculae are highly organized sheets of cardiomyocytes
that protrude toward the light of the ventricles [3]. Trabeculae are the first structural
landmark of the developing ventricles [31]. They increase the ventricular surface
and allow the myocardium to grow in the absence of coronary vessels that will be
formed later. Trabeculae are important for contractibility, formation of the conduc-
tion system, and blood flow direction in the ventricle. Although trabeculae start to
form first in the left ventricle and later in the right ventricle, there are no differences
between these structures in the two ventricles. Formed trabeculae have no free ends
and they make the ventricle appear like a sponge [31] (Fig. 12.1b). From E10.5
onward, the ventricular myocardium has two well-defined regions, morphologically
and molecularly, the outer compact myocardium and the inner trabecular layer. The
compact myocardium is less differentiated and shows a higher proliferation rate
than the trabecular myocardium [31]. Differentiated cardiomyocytes will give rise
to the working myocardium and the conduction system [31]. After completion of
ventricular septation around E14.5, further growth and maturation of the ventricular
chambers require a complete trabecular remodeling and reorganization into an
apico-basal orientation that determines the shape of the ventricles (Fig. 12.1c).
Trabeculae become compacted and as a result there is a significant change in the
ratio of compact vs. trabecular myocardium in the ventricle. Trabeculae compac-
tion is accompanied by the hypoxia-dependent invasion of the coronary vasculature
from the epicardium into the compact layer of the myocardium [33]. As they
compact, the intertrabecular recesses are transformed into capillaries of the rising
coronary plexus. This is followed by a reorganization of the muscle fibers of the
heart that organize in a three-layered spiral around the heart reflecting the twisting
pattern of heart contraction [31]. Trabeculae stop proliferating while the prolifera-
tion of the compact zone sustains the growth of the chamber and the contribution of
the compact layer to the heart becomes more significant than the one of the luminal
trabeculations that will eventually disappear. How exactly this happens and what
molecular mechanisms drive this process is unknown.
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Fig. 12.1 Overview of early heart development. (a) Ventral views of the developing mouse
embryo. At E7.0, cardiac progenitors (yellow) migrate to the center of the embryo to form the
cardiac tube and at E7.5, two cardiac fields can be distinguished: the first heart field (FHF; yellow)
and the second heart field (SHF; green). By E8.0, the cardiac tube is formed where endocardium
and myocardium are already present. At E9.0 the tube loops and at E9.5, has four anatomically
distinct regions: atrium, atrioventricular canal (AVC), ventricle (V), and outflow tract (OFT).
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12.2 Left Ventricular Non-compaction (LVNC)
LVNC is a cardiomyopathy of poorly understood etiology that is characterized by
prominent and excessive trabeculations with deep recesses in the ventricular wall
[18]. LVNC was first diagnosed in 1984, in a 33-year-old woman assessed by
echocardiography [10]. Since then, the heterogeneity of its symptoms might have
left many LVNC cases undiagnosed [18], giving a lower estimation of its real
impact as a cardiomyopathy. The improvement in imaging technologies and the
advent of CMRI allow now a better diagnosis of this disease, and 10 years after the
first description, LVNC was included in the World Health Organization (WHO)
catalogue of cardiomyopathies [30]. In 2006, the American Heart Association
included LVNC to its list of genetic cardiomyopathies caused by an arrest of the
normal compaction process of the developing myocardium [23]. LVNC can be
almost asymptomatic or manifest as depressed systolic function [7], accompanied
by systemic embolism, malignant arrhythmias, heart failure, and sudden death [25],
although its clinical manifestation and the age of the affected individual at symptom
onset are variable. LVNC was shown to be caused by mutations in genes encoding
mainly structural proteins of the cardiac muscle, cytoskeleton, nuclear membrane,
and chaperone proteins. In general, familial forms of LVNC are transmitted as an
autosomal-dominant trait [7]. The underlying molecular mechanisms that produce
the structural abnormalities leading to LVNC are still unknown [34].
12.3 The NOTCH Signaling Pathway
Notch is a conserved signaling pathway that regulates cell fate specification,
differentiation, and tissue patterning via local cell interactions [2]. There are four
Notch receptors in mammals, Notch1–Notch4, which are expressed in different
tissues and at different times during embryonic and adult life. Notch is a large type I
transmembrane receptor that has two distinct domains, an extracellular domain
(NECD) responsible for the interaction with the ligands and an intracellular domain
(NICD) responsible for signal transduction (Fig. 12.2). NECD contains a varied
number of tandem arrays of epidermal growth factor (EGF)-like repeats [2]. NICD
is composed of the RAM23 domain and 6 ankyrin repetitions responsible for the
interaction with RBPJK, the transcriptional effector of the pathway; two nuclear
localization signals; a transcriptional activation domain only present in Notch1 and
Notch2; and a terminal PEST domain that negatively regulates the stability of the
receptor [21]. NECD and NICD are synthesized as a single polypeptide, which is
directly cleaved after translation by a furin convertase in the Golgi. This first
Fig. 12.1 (continued) Endocardial cushions are formed in valvulogenic regions of the heart
(green, OFT and blue, AVC) and trabeculae appear in the ventricles (b). At E15.5, trabeculae
are undergoing compaction and there is a thick compact myocardium (c) that becomes very
prominent in the adult ventricle that has a smooth surface (d)
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cleavage [6] is necessary to form the functional heterodimeric receptor that will be
translocated to the membrane where the two domains are still associated by Ca2þ-
dependent non-covalent bonds [28]. In mammals, the Notch ligands belong to the
Delta-like (Dll1, Dll3, and Dll4) and Jagged (Jag1 and Jag2) families. The ligands
Fig. 12.2 The Notch signaling pathway. The Notch ligands Delta and Jagged are tethered to the
membrane of the signaling cell. On their way to the plasmatic membrane, the Notch receptors are
modified in their extracellular domains (NECD) by Fringe. Upon ligand-receptor interaction, Mib1
ubiquitylates the ligand, targeting it for endocytosis. Pulling of NECD allows the cleavage and
release of NICD by γ-secretase. NICD translocates to the nucleus and forms a transcriptional
activation complex together with RBPJK and MAML that activates target genes transcription,
including Hes and Hey that encode transcriptional repressors
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are type I transmembrane proteins and their extracellular domains are composed by
a repetition of EGF-like domains responsible for the interaction with the receptor
and the DSL (Delta, Serrate, Lin12) domain (Fig. 12.2) [21]. The glycosyl-
transferase Fringe can modify the EGF-like domain in the NECD of the receptor
by adding O-fucose glycans [5] (Fig. 12.2). This modification determines which
ligand preferentially binds to the receptor. There is evidence that the presence of
Fringe shifts the activation balance toward Delta-like ligands at the expense of
Jagged ligands when both molecules are expressed at the same time in the same
tissue [4]. The E3 ubiquitin ligase Mind bomb1 (Mib1) regulates the endocytosis of
the Notch ligands when bound to NECD, a prerequisite for Notch activation
[16]. Mib1 binds to the two families of Notch ligands, and it is a point of regulation
of the pathway in the signaling cell. Upon interaction of ligand and receptor, Mib1
targets by ubiquitylation the ligand for endocytosis [16]. The ligands are
endocytosed, mechanically pulling NECD producing a conformational change
that exposes a second cleavage site [27] allowing a metalloprotease of the
ADAM family to cleave NECD [13] that is finally endocytosed into the signaling
cell together with the ligand. Immediately after, γ-secretase/Presenilin cleaves the
receptor in a third site liberating the NICD in the cytoplasm of the receiving cell
[26] (Fig. 12.2). NICD translocates to the nucleus where it binds to the transcription
factor CSL or RBPJK via by the RAM23 domain [32]. In the absence of Notch
signaling activation, RBPJK is bound to nuclear corepressors that inhibit gene
expression. Upon the interaction of NICD with RBPJK, the transcriptional
repressors are released and transcriptional activators such as Master mind-like
(Maml) [35] are recruited forming a protein complex that activates the expression
of target genes (Fig. 12.2).
12.4 NOTCH in Ventricular Chamber Development
Notch pathway elements show a complex expression pattern in the developing
mouse chambers. At E9.5, Mib1 is expressed in endocardium and myocardium,
Dll4 in the endocardium especially at the base of the forming trabeculae, Jag1 in the
myocardium, and N1ICD is only active at discrete sites where the trabeculae form
[9]. Analysis of standard and endothelial-specific Notch1 and RBPJkmutants shows
that trabeculation is severely impaired and only primitive, poorly organized
trabeculae can be observed in these mutants [12]. Molecular analysis indicates
that during trabeculation, Notch modulates three different signals: EphrinB2 [1],
expressed in the endocardium, is a direct Notch target. Nrg1 [15], also expressed in
the endocardium, is an indirect Notch target, and its expression depends both of
Notch and EphrinB2 [12]. Nrg1 induces the formation of the ventricular conduction
system, a feature of ventricular maturation [29]. A third signaling pathway is
Bmp10 [8], expressed in trabecular myocardium and whose expression is severely
downregulated in Notch pathway mutants, suggesting that Notch is required to
produce a signal that activates Bmp10 in the myocardium [12]. During these early
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stages, the ligand Dll4 is the main Notch activator in the endocardium [12]
(Fig. 12.3).
To precisely determine the contribution of Notch ligands to ventricular chamber
development, we bred mice bearing a conditional allele ofMib1 with myocardium-
specific Cre driver line cTnT-Cre [19]. Histological examination at E16.5 revealed
thatMib1flox;cTnT-Cremutants had a dilated heart with a thin compact myocardium
and large, non-compacted trabeculae, protruding toward the ventricular lumen.
Morphological and functional analysis using echocardiography and cardiac mag-
netic resonance imaging (CMRI) showed prominent trabeculations, deep
intertrabecular recesses, and a significantly reduced ejection fraction in mutant
mice [22]. The hearts of these mice had a ratio of non-compacted to compacted
myocardium (non-compaction index, NC) of 2.0, a feature diagnostic of LVNC in
humans [11, 17]. These features are all strongly reminiscent of LVNC, establishing
Mib1flox;cTnT-Cre mice as the first animal model of LVNC [22]. Analysis of
chamber markers in E15.5 Mib1flox;cTnT-Cre mice revealed expansion of various
compact myocardium markers (Hey2, Tbx20 and n-myc) to the trabeculae and
Fig. 12.3 Proposed
mechanism of Notch function
in trabeculation. (a, b detail)
Dll4 activates Notch1 at the
base of the developing
trabeculae. N1ICD/RBPJK
activates EphrinB2(Efnb2)/
EphB4 signaling in the
endocardium, which in turn is
required for Nrg1 expression
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reduced expression of the trabecular markers Anf, Bmp10, and Cx40. These markers
were normally expressed at earlier stages, suggesting that maintenance of
trabecular maturation and patterning is impaired in Mib1flox;cTnT-Cre mutants.
Likewise, lost or reduced Hey1, Hey3, and EphrinB2 expression in the vessels of
the compact myocardium suggested that coronary artery development was defec-
tive. Proliferation analysis revealed increased proliferation of trabecular
cardiomyocytes in the hearts of E15.5 Mib1flox;cTnT-Cre embryos, suggesting
this as the cause of the enlarged, non-compacted trabeculae in these mutants.
RNA sequencing analysis of E14.5 Mib1flox;cTnT-Cre mutant ventricles identified
altered expression of 315 genes (132 upregulated and 183 downregulated). The
expression of genes involved in the differentiation of cardiac endothelium/endo-
cardium and cardiomyocytes and coronary vasculogenesis was altered. RNA-Seq
data also confirmed the in situ hybridization analysis and demonstrated that Mib1
inactivation in the myocardium disrupts the differentiation and maturation of
cardiac endothelial cells and cardiomyocytes. This may impact in turn the process
of ventricular maturation and compaction. Genetic ablation ofMib1 in the myocar-
dium thus leads to LVNC cardiomyopathy in mice by arresting ventricular
trabeculae maturation and compaction and increasing cardiomyocyte proliferation
during fetal development [22].
We next examined whether mutations in the human MIB1 homologue were
associated with clinical LVNC and identified two mutations in a cohort of
100 Southern European LVNC cases; one was a heterozygous G to T transversion
of nucleotide 2827 in exon 20 (causing a change in amino acid 943 from valine to
phenylalanine, the p.Val943Phe mutation). Val943 is located within a region that
mediates protein-protein interactions and constitutes the site of MIB1 ubiquitin
ligase activity. The second mutation was a heterozygous C to T transition of
nucleotide 1587 in MIB1 exon 11 (causing a premature stop codon instead of
arginine at position 530 in the MIB1 ankyrin repeats region, the p.Arg530X
mutation). These two mutations were tracked back through three and two
generations of LVNC-affected individuals, revealing co-segregation with LVNC,
confirming the hereditary nature of the disease [22].
In silico modeling suggested that MIB1 is a homodimer where the p.Val943Phe
mutant will alter the alignment of the ring finger domains in heterodimers formed
by wild-type and mutant p.Val943Phe MIB1, as well as the angle of interaction
with JAG1 of the p.Val943Phe wild-type dimers. This possibility was supported by
co-immunoprecipitation experiments with tagged wild-type MIB1 and mutant
MIB1 isoforms co-transfected in pair-wise combinations into HEK293 cells. The
effect of the MIB1 mutations on Jag1 ubiquitylation was tested also in HEK293
cells. Jag1 ubiquitylation was strongly reduced in cells co-transfected with wild-
type MIB1 plus p.Val934Phe or wild-type MIB1 plus the p.Arg530X mutant [22].
Lastly, to study the effect of these mutant MIB1 variants in vivo, their mRNAs
were microinjected into zebra fish embryos expressing GFP in the developing
myocardium. Examination of 72 hpf larvae injected with p.Val943Phe or p.
Arg530X mRNAs revealed severely disrupted embryonic development, disrupted
cardiac looping, and kinked tail, typical of defective Notch activity. To complement
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these findings, we cocultured Jag1-HEK293 cells expressing MIB1 variants with
Notch1-expressing HEK293 cells co-transfected with a Notch luciferase reporter.
Jag1-HEK293 cells expressing wild-type MIB1 increased Notch reporter activity,
whereas the p.Val934Phe and p.Arg530X mutant forms reduced reporter activity,
indicating that both human mutations disrupt Notch signaling [22].
Accumulated data suggested that both MIB1 mutations result in loss of MIB1
WT function. In the case of p.Arg530X, this would be due to haploinsufficiency
caused by insufficient synthesis of WT MIB1 protein; in the case of p.Val934Phe,
this would be due to a dominant-negative effect of the mutant protein, titrating
down the amount of functional WTMIB1 dimers through heterotypic or homotypic
interactions. In both cases, loss of MIB1 function leads to disease inherited in an
autosomal-dominant fashion.
As to the role of Mib1 in ventricular chamber development, we have proposed
that myocardial Mib1 activity enables Jag1-mediated activation of Notch1 in the
endocardium, to sustain trabeculae patterning, maturation, and compaction [22] and
(Fig. 12.4). Abrogation of Mib1-mediated signaling in the myocardium disrupts
trabeculae maturation and patterning, arresting the development of chamber myo-
cardium and resulting in LVNC (Fig. 12.4). The expansion of compact zone
markers to the trabeculae of E15.5 Mib1flox;cTnT-Cre mutants further suggests
that trabeculae patterning and maturation is impaired (Fig. 12.4). In addition, the
disruption of coronary vessel markers in Mib1flox;cTnT-Cre mutants indicates that
abrogation of myocardial-endocardial Notch signaling indirectly impairs coronary
vessel formation.
12.5 Future Directions and Clinical Implications
The data reviewed here establish the causal role of NOTCH dysregulation in
LVNC, a congenital cardiomyopathy that results from a developmental arrest in
ventricular maturation and myocardial compaction. These findings will lead to a
better diagnosis and risk stratification, allowing timely intervention in LVNC-
associated complications. In addition, since other NOTCH pathway elements may
be involved in LVNC, they could serve as novel diagnostic or therapeutic disease
targets. Further research is required to determine the molecular mechanisms and
regulatory interactions underlying NOTCH function in ventricular chamber devel-
opment using genetically modified mouse models and the full implication of altered
NOTCH signaling in human LVNC.
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Fig. 12.4 Proposed mechanism of Notch function in trabecular maturation and compaction. (a) In
wild-type (WT) embryos, ubiquitylation of Jag1 (and another ligand?) by Mib1 in the myocardium
allows Notch1 activation in the endocardium. N1ICD is required to sustain trabecular patterning,
maturation, and compaction. The compact myocardium (expressing Hey2, Tbx20 and n-myc)
proliferates actively, unlike the trabecular myocardium (expressing Anf, Bmp10 and Cx40).
Notch-dependent chamber maturation leads to compacted ventricular myocardium in the adult
mouse. (b) In Mib1flox; cTnT-Cre mutants, Notch1 activity is impaired and compact myocardium
markers (Hey2, Tbx20 and n-myc) are consequently expanded to the trabeculae, which remain
abnormally proliferative. The resulting disruption of trabecular patterning, maturation, and com-
paction manifests as LVNC (Modified from [22])
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